Litcius/Paper detail

292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial

S. Loibl, Michael Untch, Jens Huober, V. Schaser, Michael Braun, Carsten Denkert, Andreas D. Hartkopf, Jens‐Uwe Blohmer, Claus Hanusch, Theresa Link, Mattea Reinisch, D-M. Zahm, R. Weide, Vesna Bjelic‐Radisic, Peter Staib, Hans Tesch, Kerstin Rhiem, R. Lorenz, Julia Rey, Andreas Schneeweiß

2025Annals of Oncology5 citationsDOI

Topics & Concepts

MedicineDurvalumabOncologyInternal medicineChemotherapyBreast cancerPlaceboNeoadjuvant therapyOverall survivalClinical endpointClinical trialSurvival analysisCancerPhases of clinical researchChemotherapy regimenSurvival rateChemoradiotherapySurrogate endpointBreast Cancer Treatment StudiesMedical Imaging Techniques and ApplicationsCancer Immunotherapy and Biomarkers
292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial | Litcius